ANTI-REMODELING THERAPY TO PATIENTS WITH CHRONIC HEART FAILURE AND METABOLIC SYNDROME (22-26)

Архив в PDF формате
Дата публикации статьи в журнале: 2020/02/17
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 53, Том: 2, Страницы в выпуске: 22-26
Автор: Atakhodzhaeva Gulchekhra Abdunabievna
, Tashkent Pediatric Medical Institute, DSc
Автор: Baratova Dilorom Sadirovna
, Tashkent Pediatric Medical Institute,
Анотация: The aim of this work is to study the anti-remodeling efficiency of complex pharmacotherapy of CHF by use of perindopril, spironolacton and bisoprolol in patients with MS. The study involved 106 male patients with chronic heart failure (CHF) II-III FC, with post infarction cardiosclerosis. Depending on the components of MS the patients were divided into 3 groups: Ist group (n=37), patients without MS; Group II (n=34), patients with a combination of dyslipidemia (DLP) with abdominal obesity (AO) and arterial hypertension (AH); Group III (n=35), patients with a combination of AD, AH and DLP with diabetes 2 types. The MS in patients with chronic heart failure reduces the anti-remodeling effectiveness of the combined application of Perindopril, Bisoprolol and Spironolacton, which depends on the representation of its components. The most marked resistance against therapy exists, when there is a combination of AO, AH and DLP with diabetes of 2 types.
Ключевые слова: chronic heart failure   metabolic syndrome   systolic and diastolic left ventricular dysfunction   
Данные для цитирования: Atakhodzhaeva Gulchekhra Abdunabievna, Baratova Dilorom Sadirovna, . ANTI-REMODELING THERAPY TO PATIENTS WITH CHRONIC HEART FAILURE AND METABOLIC SYNDROME (22-26). Восточно Европейский Научный Журнал. Медицинские науки. 2020/02/17; 53(2):22-26.

Список литературы: 1. Ageev F.T., Mareev V.Y., Belenkov Y.N. Heart failure on the background of coronary heart disease: some questions of epidemiology, pathogenesis and treatment. // Russian medical magazine - 2000; T.8.-№15 / 16: 26-28. 2. Gurevich M.A. The role of ACE inhibitors in the treatment of heart failure. Clinic Medicine 2004; 2: 4-9. 3. Belenkov Y.N. Chronic heart failure: medical and economic aspects of treatment. The Doctor 2002; 12: 3-7. 4. Zeller M., Steg P., Ravisy J. et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarctio //Arch. Intern. Med.2005;10:1192-1198. 5. Levantesi G., MaccHia A., Marfisi R.M. et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction //J. Am. Coll. Cardiol.2005;2:277-283. 6. De Simone G., Paganisi F., Contaldo F. Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hipertention 2001; 38:13-18. 7. Conradi A.O., Zhukova A.V., Winnick T.A., Shlyakhto E.V. Structural and functional parameters of the myocardium in patients with hypertension, depending on body weight, such as obesity and the state of carbohydrate metabolism. Arter. Hyper. 2002; 8: 1: 12-17. 8. Aleksandrov A.A., PoddubskayaE.A.The geometry of the left ventricle, arterial hypertension and obesity: the search for new ways of prevention. Prof. Zabol. Strengthening the Health. 2003; 5: 6-11. 9. Schirmer H., Lunde P., Rasmussen K. Prevalence of left ventricular hypertrophy in general population. The Tomso Study. Eur. Heart J. 1999;20:429-438. 10. Ageev F.T., Mareev V.Y., Belenkov Y.N. Heart failure on the background of coronary heart disease, some questions of epidemiology, pathogenesis and treatment .// Russian medical magazine - 2000; T.8.-№15 / 16: 26-28 11. Kenchaiah S. EvansJ.C., Levy D. et al. Obesity and the risk of heart failure //N.Engl.J.Med.2002;347:305-313. 12. Teicholz L.E., Kruelen T., Herman M.V. et al. Problems in echocardiographic volume determination. // Am. J. of Cаrdiol.1976;37:7-11. 13. Devereux R.B., Lunas E.M., Kasale P.M. et al. Standartization of M-mode echocardiographic left ventricular anatomic measurements. J.Amer. Col Cardiol. 1984;4:1222-1230. 14. Mamedov M.N. Metabolic syndrome. The features of diagnosing in clinical ambulatory conditions. Appendix to the magazine. The Treating Doctor 2000; 6: 11-14 15. Makolkin V.I., Podzolkov V.I., Napalkov D.A. Metabolic syndrome from the point of view of cardiologist: diagnostics, non-drug and drug treatments. Cardiology 2002; 12: 91-96. 16. Glebovskaya T.D., Burova N.N., Solovyov N,V, The role of the disturbance of diastolic myocardial function in heart failure in patients with metabolic syndrome, undergoing myocardial infarction-segment elevation ST. // Hypertension 2010; 2170-174. 17. Vigdorchik V.I., Prokopenko V.D., Simonov, D.V. Diastolic function of the left ventricle in patients with hypertension associated with metabolic syndrome .// Vest.Nov.med.tehnol.2004; 4: 57-59. 18. Mammadov M.N., Gorbunov V.M., Kiseleva N.V., Oganov R.G. Features of structural and functional changes in the myocardium and hemodynamic disturbances in patients with metabolic syndrome: the role of hypertension in the formation of the total coronary risk .// Cardiology 2005; 11: 11-16. 19. Messery F.H. Left ventricular hypertrophy as a coronary risk factor. // Blood 1992;1:28-30. 20. Galderesi M. Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. // Cardiovasc. Ultrasaund.2005;3:9:1-14. 21. Fuentes L., Brown A.L. et al. Metabolic syndrome IS associated WITH abnormal left ventricular diastolic function independent of LV mass//Eur.Heart J. 2007; 5: 553-559. 22. Kamyshnikova L.A., Efremova O.A.Treatment of diastolic dysfunction in patients with chronic heart failure .// Scientific Magazine. Medical series. Pharmacy 2010; 4: 11-16. 23. Nadeem N.M. Aldzhibrin The role of Candesartan and Perindopril in the treatment of diastolic dysfunction in patients with CHF.// Bulletin of Biology and Medicine. 2011;3: 94-97.